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Objective. Arguing that additional symptoms should be added to the criteria for atypical depression. Method. Published research
articles on atypical depression are reviewed. Results. (1) The original studies upon which the criteria for atypical depression were
based cited fatigue, insomnia, pain, and loss of weight as characteristic symptoms. (2) Several studies of DSM depressive criteria
found patients with atypical depression to exhibit high levels of insomnia, fatigue, and loss of appetite/weight. (3) Several studies
have found atypical depression to be comorbid with headaches, bulimia, and body image issues. (4) Most probands who report
atypical depression meet criteria for “somatic depression,” defined as depression associated with several of disordered eating,
poor body image, headaches, fatigue, and insomnia. The gender difference in prevalence of atypical depression results from its
overlap with somatic depression. Somatic depression is associated with psychosocial measures related to gender, linking it with the
descriptions of atypical depression as “reactive” appearing in the studies upon which the original criteria for atypical depression
were based. Conclusion. Insomnia, disordered eating, poor body image, and aches/pains should be added as criteria for atypical
depression matching criteria for somatic depression defining a reactive depressive disorder possibly distinct from endogenous
melancholic depression.

1. Introduction
Much research has been done on atypical depression, which
appears in the DSM as a specifier for major depression
[1]. Some of this research has suggested that changes be
made in the criteria for atypical depression but very little
of this research has dealt with the possibility of adding
to the original criteria. This paper reviews four bodies of
research that support the case for adding criteria. The focus
here is on disordered eating and poor body image, pain,
insomnia, and fatigue (although some interpret the leaden
paralysis criterion as extreme fatigue) [2, 3]. Evidence is
presented suggesting that the broadened criteria define a
nonendogenous depressive disorder.

2. Argument 1: Studies That Served as the
Basis of the Criteria for Atypical Depression
The existence of atypical depression grew out of work on
response to antidepressant medication. Reviews of case studies [4, 5] suggested that some patients exhibiting a syndrome
labelled “atypical depression” responded better to treatment
with MAOIs than with tricyclic antidepressants. Based in
large part on these case studies, researchers from Columbia
University reviewed a series of empirical clinical studies
that indicated that patients with some forms of depression
responded better to MAOIs than to placebos while most
patients exhibiting endogenous depression probably did not
[6]. At the end of this review, the authors hypothesized the

2
existence of an atypical depression involving lethargy, hypersomnolence, hyperphagia, rejection sensitivity, and reactivity
of mood. By 1988, the Columbia group had shown that
patients exhibiting these symptoms did respond more to
phenelzine than to imipramine or placebo [7] and suggested
that atypical depression be included in the DSM. This
suggestion was first implemented in DSM-IV and atypical
depression has been included as a specifier of major depressive disorder in all versions of the DSM since then.
The narrow version of the first argument for broadening
the criteria is based upon details of the symptoms mentioned
in the original case studies defining atypical depression and
measured in the research studies reviewed by the Columbia
group. In an early clinical review, West and Dally [4] summarized the characteristics of the patients with what they
termed “atypical or hysterical” depression whom they found
to be helped by the MAOI iproniazid. Included among the
symptoms exhibited by these patients were fatigue, inability
to fall asleep at night, and psychosomatic symptoms. While
the authors noted that “weight loss was not a constant”
(page 1492), they also wrote that, in response to the drug
treatment, “weight gain might be rapid with a noticeable
increase in appetite” (page 1493). No mention was made in
the article of hypersomnia or overeating. In a related article
on antidepressants, Sargant [5] described atypical depressives
as “patients suffering from neurotic or reactive depressive
illnesses or even sometimes from anxiety hysteria” (page 226).
Characteristic symptoms mentioned in the article included
general fatigue, pains, and considerable loss of weight. Again,
no mention was made of hypersomnia (although both
articles mentioned that atypical depressives often woke up
fatigued after a long night’s sleep) or of overeating. These
authors contrasted endogenous depression with the atypical
depression that responds to MAOIs. Subsequently, Paykel
et al. [8] reported that a definition of atypical depression
emphasizing reversed functional shift such as insomnia was
related to measures of nonendogenous depression and noted
that their findings demonstrated that “one of the clearest
operational measures for atypical depression in the literature
was confirmed. . . as a global measure of nonendogenous
depression” (page 137).
About two decades later, Quitkin et al. [6] reviewed
clinical research studies on response to MAOIs, particularly
phenelzine. In a table, the authors summarized all studies
comparing phenelzine and placebo in “neurotic or atypical
depressives” (page 754). In the tabulated list of symptoms
and characteristics that had been used to select the patients
in the studies that demonstrated relatively good response to
the MAOI were included difficulty falling asleep, fatigue, and
atypical facial pain. Most of these studies simply described the
patients as suffering from neurotic depression. Hypersomnia,
overeating, and rejection sensitivity were not included in the
table that served as the basis for concluding that “phenelzine
is clearly effective in neurotic or atypical depressives” (page
749). Yet, at the end of the article, the authors suggested that
MAO inhibitors be the first antidepressants used in treating
“depressed patients with atypical features such as lethargy,
hypersomnolence, hyperphagia, rejection sensitivity, and
reactivity of mood” (page 759). Subsequently, the Columbia
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group performed their own study that found better response
to phenelzine compared to imipramine or placebo among
patients exhibiting depressive illness having reactive mood,
plus at least one of four associated symptoms: hyperphagia,
hypersomnolence, leaden feeling, and sensitivity to rejection
[7]. They called for including these criteria as a separate
category of atypical depression in the DSM.
In the argument presented here for broadening the
criteria for atypical depression, this narrow emphasis on the
particular symptoms included in these early articles but not
included in the criteria for atypical depression that were
created based upon these studies may be no more significant
than a more general point. That is, in the original summary of
research on MAOI response [6], the Columbia group noted
that many of the studies they reviewed were done prior to
DSM-III without detailed operationalization of the patients
treated. They described most of the studies as dealing with
patients that were not endogenous but were “inadequately
characterized” (page 751), usually only described as exhibiting
neurotic depression. They noted that the criteria they suggested for patients best treated with MAOIs were based on
clinical impression.
This is not to suggest that the criteria were simply
wrong. Scores of subsequent studies have demonstrated the
usefulness of the concept of atypical depression (although
it may not necessarily be so atypical) including more recent
reviews of the preferential response of atypical depression to
MAOIs [9]. The work of the Columbia group and some others
that have done much of the research has been extremely
useful. Later work done by several investigators has discussed
changes that might be made to the original criteria, such as
eliminating the necessity for exhibiting mood reactivity [10],
according primacy to rejection sensitivity [11], or eliminating
the trait features of mood reactivity and rejection sensitivity
while focusing on the state features of hypersomnia and
overeating and perhaps leaden paralysis [12]. But, with the
exception of some studies of the possible role played by panic
[13] and of age of onset and chronicity [14, 15], only one study
[16] to our knowledge has suggested adding symptoms to the
criteria. That is, a set of criteria based upon clinical judgement
of some similarities between studies of response to MAOIs
has, for the most part, been reified such that they are either
applied as originally suggested or reordered in some way.
That many of the early cases and research studies considered
atypical depression to be a form of nonendogenous reactive
depression and explicitly included insomnia, pain, weight
loss, and fatigue has been ignored and left out of subsequent
research.

3. Argument 2: Studies of
the Prevalence of the Individual Symptoms
of Atypical Depression
This section deals with symptoms that are included in the
current DSM criteria for major depression. Some studies
have measured the extent to which respondents who exhibit
syndromes related to atypical depression report the various
depressive criteria.
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Seemüller et al. [17] measured symptoms reported by
depressed patients on the Hamilton Scale for Depression
(HAMD-21) in nine psychiatric hospitals in Germany. 127
patients met criteria for atypical depression. It should be
noted that some of the criteria were approximated. For rejection sensitivity, Seemüller et al. used a measure of irritability
and for leaden paralysis a measure of heaviness in legs. Of
the patients with atypical depression, 63% reported early
insomnia, 72% reported middle insomnia, 38% reported loss
of weight, 52% reported loss of appetite, and 93% reported
somatic symptoms, which were comprised of heaviness of
limbs, aches, or fatigue.
An analysis of correlates of atypical depression was performed on data from the Children in the Community study,
a longitudinal study of a systematic sample of households
that had children aged 1–10 in 1977 living in two counties
in New York State [16]. The data were from 1987, when
respondents were 11–22. Respondents were categorized as
exhibiting atypical depression if either the respondent or the
respondent’s mother reported that the respondent had at least
a 2-week period of depressed mood but not a 2-week period
of anhedonia and exhibited at least two of the following:
excessive eating or weight gain during the period, excessive
sleep or long naps for 2 weeks, leaden paralysis (which
may have been difficult for mothers to infer from behavior)
for at least 2 weeks, and scoring at least one standard
deviation above the mean on a scale of items measuring
rejection sensitivity. The proportion of atypical respondents
who generally took at least 30 minutes to fall asleep was 42%
and 63% characterized themselves as exhibiting insomnia.
The other studies described in this section did not use
the criteria for atypical depression related to mood reactivity,
leaden paralysis, and enduring rejection sensitivity. Angst
et al. [2] described symptoms reported by respondents
characterized as exhibiting atypical depression in the Zurich
study, a sample representative of the Swiss canton of Zurich.
37 respondents met criteria for major depressive disorder
and reported at least two of overeating, oversleeping, and
excessive physical fatigue. Of these, 51% reported increased
appetite compared to 54% who reported loss of appetite,
43% reported weight gain compared to 38% who reported
weight loss, and 89% reported hypersomnia compared to 78%
who reported insomnia. Pollitt and Young [18] found little
difference between early and late insomnia among patients
who responded to MAOIs versus those who did not.
Also of interest are studies that have reported the frequencies of depressive criteria exhibited by respondents who
were categorized as belonging in subtypes resembling atypical
depression found in latent class analyses (LCAs). Sullivan
et al. [19] found one subtype of depression in a LCA of
data from the National Comorbidity Survey characterized
by “nearly universal presence of major depression and the
preponderance of classical depressive symptoms (i.e. weight
and appetite loss, insomnia, psychomotor retardation, anergia, and poor concentration)” (page 1400) that they labelled
“severe typical.” The “severe atypical” subtype was characterized by the presence of major depression and appetite
increase and weight gain along with sleep problems. Of
the respondents in the severe atypical class, 39% exhibited
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appetite decrease, 40% exhibited weight decrease, 87% exhibited insomnia which was higher than the 54% of respondents
in the severe atypical class who reported hypersomnia, and
92% of respondents in both the severe atypical and the severe
typical classes exhibited tiredness/lack of energy.
Based upon a LCA of data from 488 respondents in the
Netherlands Study of Depression and Anxiety, Lamers et
al. [20] designated one class of respondents as exhibiting
severe typical depression and another as exhibiting severe
atypical depression. The severe typical class was characterized
by decreased appetite, weight loss, and insomnia, whereas the
severe atypical class was characterized by “increased appetite
and weight gain” (page 2086). Separate LCAs were performed
two years apart. Among respondents belonging to the severe
atypical class in both analyses, the probability of fatigue was
extremely high, the probability of weight loss or decreased
appetite was extremely low, and the probability of insomnia
was distinctly greater than the probability of hypersomnia.
LCAs performed on data from the Zurich study by Rodgers et
al. [21] arrived at similar results which will not be described
here as the same database was analyzed in the Angst et al. [2]
study described above.
Some of the studies reviewed in this section did not apply
strict DSM criteria. Nonetheless, the syndromes resembling
atypical depression described in all of these studies clearly
involve vegetative symptoms in addition to those commonly
referred to as “reversed.” The studies based on latent class
analyses reported low levels of weight loss and decreased
appetite but they reported very high levels of insomnia and
fatigue. The studies that applied modified criteria for atypical
depression to a large sample of hospitalized patients [17] and
to a representative sample in the Zurich study [2] found that
small majorities of people meeting these criteria reported loss
of appetite and large majorities reported insomnia (fatigue
was one of the criteria in the Angst et al. study and subsumed
under a larger category of somatic symptoms in the Seemüller
et al. study).
The characterization of atypical depression as involving
reversed vegetative symptoms has been extremely useful in
the recognition of the distinct nature of the syndrome. Most
of the early research that led to the inclusion of atypical
depression in the DSM and much of the later research
that validated its existence were based on comparisons with
typical depression. If the criteria for atypical depression used
in these studies had included symptoms similar (but as discussed below, not necessarily identical) to typical depression,
the results of the comparisons between the two subtypes
would have been much weaker. The distinct character of
atypical depression might never have been recognized.
It was this contrast with typical depression, apparent from
the beginning even in the use of the term “atypical” in the
name, that led to conceptualizing the vegetative symptoms
of atypical depression as only those that are reversed. But
possibly appetite loss and certainly insomnia are common
among people with atypical depression. Does it make sense
to eliminate them from the criteria simply because they
resemble symptoms of typical depression? It is possible that
the insomnia exhibited by people with typical depression
arises from endogenous distortions in neurotransmitters
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while the insomnia exhibited by people with atypical depression arises from nonendogenous anxiety. It is also possible
that the loss of appetite/weight exhibited by people with
typical depression also arises from endogenous distortions in
neurotransmitters while the loss of appetite/weight reported
by several people who exhibit atypical depression is related to
nonendogenous, psychosocially based disordered eating, as
discussed below. Whether or not these hypotheses eventually
receive support, should the criteria for a disorder be chosen
based upon characteristics that another disorder does not
have? Following this logic that seems to have been used
to eliminate appetite loss and insomnia from criteria for
atypical depression would result in eliminating depression
from criteria for bipolar disorder because it also characterizes
major depression.

4. Argument 3: Studies of
Symptoms/Disorders That Are Comorbid
with Atypical Depression
The symptoms focused on in this paper that are not included
in current criteria for major depression have been reported
to be comorbid with atypical depression in several studies,
although the exact prevalence of the comorbid symptoms and
disorders found in these studies varies. This is likely due to the
variation between these studies in the samples analyzed and
the definitions of atypical depression utilized.
In the Zurich study described above [2], 68% of respondents exhibiting major depression with atypical features
reported symptoms characteristic of a broad definition of
migraine headache. The analysis of data from the Children
in the Community study [16] found that 47% of atypical
respondents reported headaches/stomachaches. These results
confirm the conclusion made by Davidson et al. [22] as
early as 1985 based upon an analysis of patients with chronic
pain that there exists an important link between atypical
depression and chronic pain.
Several studies have reported a relationship between
bulimia/binge eating and atypical depression. Kendler et al.
[23] performed a latent class analysis applied to 14 disaggregated DSM-III-R symptoms for major depression reported by
members of 1029 female-female twin pairs. They found high
lifetime rates of bulimia (19%) in the group defined by this
LCA as exhibiting atypical depression.
Among respondents in the Zurich study who met criteria
for major depressive disorder and reported at least two of
overeating, oversleeping, and excessive physical fatigue, eight
percent reported bulimia and 19% reported binge eating [2].
Posternak and Zimmerman [24] evaluated 579 psychiatric
outpatients with a current diagnosis of major depressive
disorder for the presence of atypical features. Of those
meeting DSM-IV criteria for atypical depression, six percent
met criteria for bulimia. Perugi et al. [25] examined in a
semistructured format 107 consecutive patients who met
DSM-IV criteria for a major depressive episode with atypical
features. They found that 18% of patients who met the DSMIV criteria for atypical depression also met criteria for bulimia
nervosa.
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Several studies have also found a relationship between
atypical depression and problems with body image. Nierenberg et al. [26] investigated 350 consecutive outpatient subjects with major depression who entered an antidepressant
treatment study. They found a higher rate of lifetime and
current Body Dysmorphic Disorder (BDD) in subjects with
DSM-III-R atypical depression than in those with nonatypical depression (14% compared to 5%). In a study of 86 major
depressive patients with atypical features as defined by the
DSM, 42% were found to have BDD [25]. The Posternak and
Zimmerman [24] study of psychiatric outpatients described
above also found that those with atypical depression exhibited
higher rates of BDD than those with typical depression (7%
versus 2%). The analysis of the Children in the Community
study found that 68% of respondents with atypical depression
reported experiencing fear of fat [16].
It has been noted that rather than reflecting the concomitance of two distinct disorders, in some cases, comorbidity
may actually reflect multiple manifestations of a single disorder [27]. Thus, one explanation of these patterns of alleged
comorbidity is that pain, bulimia/binge eating, and body
image issues may belong with current criteria for atypical
depression as symptoms of a single disorder. The last two
symptoms (in combination with the loss of appetite/weight
discussed above that might result from intentional food
restriction) suggest the possibility that the appetite symptoms
of atypical depression may be related to a larger pattern of
disordered eating.

5. Argument 4: Studies of Somatic Depression
The studies reviewed above suggest a possible role played
in the disorder currently diagnosed as atypical depression
by fatigue (as some have already acknowledged), insomnia,
disordered eating, poor body image, and aches/pain. This
combination indicates a similarity with somatic depression,
which has been generally defined in studies as depression plus
three of (1) fatigue, (2) insomnia, (3) disordered eating (either
bingeing, purging, or intentional food restriction), (4) poor
body image/preference for thinness, and (5) frequent severe
headaches [28]. High levels of somatic depression among
women have been hypothesized to account for the gender
difference in the prevalence of depression [29].
In an analysis of data from a representative sample in
the Zurich study [30], atypical depression was defined as
meeting DSM-III criteria for depression and reporting three
of the following: overeating, oversleeping, leaden paralysis,
mood reactivity, and rejection sensitivity. Half of the male and
the vast majority of the larger group of female respondents
(83%) who met these criteria also met criteria for somatic
depression. Fewer than 1/3 of the male and 1/6 of the female
respondents with somatic depression met criteria for atypical
depression. Thus, it might be said that atypical depression
is subsumed under the more inclusive category of somatic
depression, particularly for females. Therefore, it is possible
that some of the findings from studies of atypical depression
have been due to its overlap with somatic depression. For
example, in the Zurich study, the higher prevalence among
women compared to men of atypical depression was found to
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be due almost entirely to its overlap with somatic depression.
Women exhibited 10.2% higher lifetime prevalence of any
depression than did men. This total was made up of women
exhibiting five percent higher prevalence of depression that
met criteria for both atypical and somatic depression, 4.1%
higher prevalence of somatic depression without atypical
depression, and only 0.2% higher prevalence than men of
atypical depression without somatic depression. That is, high
levels of somatic depression among women accounted for the
gender difference in depressive prevalence whereas there was
little gender difference in atypical depression that did not
meet criteria for somatic depression. The higher prevalence
of depression among women compared to men has also been
found to be almost entirely due to the higher prevalence
among women of somatic depression in several other large
epidemiologic databases such as the National Comorbidity
Survey, the National Comorbidity Survey-Replication, and
the Epidemiologic Catchment Area Study [31].
Several published studies (reviewed in [31]) have found
that the high prevalence of somatic depression among females
is associated with measures of psychosocial issues related to
gender roles. These results are relevant here because they suggest that somatic depression is a reactive depression similar
to the early descriptions of atypical depression as a form of
reactive depression. Women who reported feeling that they
had been limited by responses to their gender, by scoring high
in studies measuring their beliefs that men lead better lives
than women, or in studies measuring their beliefs that their
fathers showed a preference for males, or in studies measuring
their beliefs that their mothers felt limited by being female,
reported high prevalence of somatic depression. Some of
the studies found women’s reports of somatic depression
to be related to reports made by their parents of attitudes
toward gender that might be expected to bother many
contemporary women who aspire to more equal treatment
than was historically given to females. These included fathers’
reports of believing in the superiority of males and mothers’
reports of having been limited by their gender. These findings
support the hypothesis that somatic depression may grow out
of reactions to psychosocial influences related to a lack of
acceptance that may be experienced by many contemporary
women who aspire to achieve in areas once considered to
be the province of men. In that sense, it is possible that
these results may be linked to both the symptom of rejection
sensitivity included in criteria for atypical depression and the
early descriptions of atypical depression as a form of reactive
depression, not an endogenous depression. On this note, in
the Star∗D study, both somatic depression [31] and atypical
depression [32] responded relatively poorly to treatment with
antidepressants such as citalopram. That somatic depression
can result from psychosocial issues that may be particularly
bothersome to contemporary “nontraditional” women may
help to explain the high prevalence of depression that has
been seen during recent decades [31].
In summary, the results of all of the studies reviewed
here suggest that the original criteria for atypical depression
should be broadened. Fatigue should be recognized separately from leaden paralysis, insomnia, headaches, and disordered eating, including bingeing as well as intentional food
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restriction, and poor body image/fear of fat should be added.
Further studies are called for as to whether the addition of
these symptoms defines a nonendogenous reactive disorder
(somatic depression) that is not simply a specifier of major
depression but perhaps a separate nonendogenous disorder
distinct from endogenous/melancholic depression.
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